Human genetics has become a cornerstone at ABY, offering transformative advantages in drug discovery and patient care. Research, including a pivotal study by ABY’s own team, has shown that leveraging human genetics can increase success rates by 2x to 4x. This significant improvement underscores the immense value genetics brings to advancing treatments and benefiting patients.
Advantages of Joining the Alliance for Genomic Discovery
- Longitudinal Electronic Medical Records:
The Alliance provides access to extensive longitudinal electronic medical records, offering a holistic view of disease progression and patient history. Unlike traditional approaches in the pharmaceutical industry, which often involve fragmented data slices for specific diseases, this resource enables a comprehensive study of individuals over time. This integrated approach helps uncover the intricate intersections of disease biology. - Diverse Cohort Representation:
The diversity of the cohort, including variations in race and socioeconomic status, plays a crucial role in understanding disease mechanisms and outcomes. A large, diverse dataset from patients within a unified healthcare system provides a robust foundation for equitable and impactful research. - Genomic Sequencing at Scale:
The addition of genomic sequencing to this rich dataset offers unparalleled power to investigate disease mechanisms and drive discovery. This combination allows researchers to explore diseases at a scale and depth previously unattainable.
Broader Implications for Healthcare and Research
This partnership not only enhances the understanding of disease biology but also serves as a model for other healthcare institutions. By demonstrating the power of integrating longitudinal medical records, diverse cohorts, and genomic data at scale, the Alliance sets a precedent for how healthcare systems can contribute to advancing precision medicine and improving patient outcomes.
